InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1方案

PK136單克隆抗體與小鼠NK1.1（也稱為CD161b/CD161c、KLRB1、NKR-P1A和Ly-55）反應。NK1.1是一種具有C型凝集素結構域的II型整合膜糖蛋白，由Klrb1c/NKR-P1C基因編碼。NK1.1在NK細胞活化和分化、IFN-γ產生、細胞毒性顆粒釋放中起作用，并被認為參與Th2細胞的產生。NK1.1主要在NK細胞上表達為二硫鍵連接的同二聚體，然而，它也在NK-T細胞上表達，這是一種罕見的T淋巴細胞群。NK 1.1僅由C57BL/6、FVB/N和NZB小鼠品系表達，不表達AKR、BALB/c、CBA/J、C3H、DBA/1、DBA/2、NOD、SJL和129品系。

艾美捷InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1：

貨號：BXC-BE0036

亞型：小鼠IgG2a，κ

推薦同種型對照：InVivoMAb小鼠IgG2a同種型對照，未知特異性

推薦稀釋液：InVivoPure pH 7.0稀釋液

偶聯：未偶聯。提供抗體偶聯服務。

免疫原：小鼠脾臟和骨髓細胞，富含NK1+細胞

報告應用：體內NK細胞耗竭、流式細胞術

配方：PBS，pH 7.0

不含穩定劑或防腐劑

內毒素：<2EU/毫克（<0.002EU/微克）

由LAL凝膠凝固測定法確定

純度：>95%

由SDS-PAGE確定

無菌性：0.2微米過濾

在無動物設施中從細胞培養上清液中純化

純化：蛋白質A

分子量：150 kDa

儲存：抗體溶液應以原始濃度在4°C下儲存。不要冷凍。

InVivoMAb抗小鼠NK1.1/InVivoMAb anti-mouse NK1.1文獻參考：

in vivo NK cell depletion

Glasner, A., et al. (2018). "NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis" Immunity 48(1): 107-119 e104.

in vivo NK cell depletion

Burrack, K. S., et al. (2018). "Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells" Immunity 48(4): 760-772 e764.

in vivo NK cell depletion

Moynihan, K. D., et al. (2016). "Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses" Nat Med. doi : 10.1038/nm.4200.

in vivo NK cell depletion, Flow Cytometry

Ludigs, K., et al. (2016). "NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions" Nat Commun 7: 10554.

in vivo NK cell depletion

Ghasemi, R., et al. (2016). "Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy" Nat Commun 7: 12878.